Regression of metastatic angiosarcoma of the skin after systemic treatment with liposome-encapsulated doxorubicin and interferon-alpha.
Jäckel
A
A
Deichmann
M
M
Waldmann
V
V
Bock
M
M
Näher
H
H
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D004337:Drug Carriers; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000821:virology; D019288:Herpesvirus 8, Human / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000821:virology; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000821:virology
D000970:Antineoplastic Agents; D004279:DNA, Viral; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008081:Liposomes; D011994:Recombinant Proteins; D004317:Doxorubicin